Enasidenib (Idhifa) is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2.
Our Medication Sheet
This sheet is coming soon. check back later to download it as an Adobe PDF.